Booking Health Expands Access to Dendritic Cell Therapy After Study Confirms Survival Benefit in Glioblastoma Patients

Langenfeld, Germany, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global medical travel platform, announced today the expansion of patient access to dendritic cell immunotherapy for recurrent glioblastoma, following the publication of new clinical trial data confirming a significant survival benefit. The announcement comes as a recent international study reported a 68% increase in median overall survival for patients treated with autologous tumor lysate-loaded dendritic cell vaccines, reinforcing the therapy’s role in addressing one of the most aggressive forms of brain cancer.

Dendritic cell presenting antigen to T-cell

Recurrent glioblastoma remains one of the deadliest forms of brain cancer. According to the Global Cancer Observatory (GLOBOCAN), over 300,000 new cases of brain and central nervous system tumors were diagnosed globally in 2022, with glioblastoma multiforme (GBM) accounting for the majority of malignant brain tumors in adults. Today, researchers emphasize the growing role of immunotherapy for glioblastoma, since conventional treatments often fail to prevent recurrence due to the tumor's infiltrative nature and resistance to systemic treatment.

A new approach – dendritic cell therapy – is transforming the way this recurrent disease is treated. By training the patient's immune system to recognize and destroy tumor cells, this advanced immunotherapy is extending survival and reshaping clinical strategies for glioblastoma patients worldwide. Through Booking Health, international patients can now access innovative dendritic cell therapy at leading neuro-oncology clinics across Europe.

Why Recurrent Glioblastoma Remains One of the Most Challenging Cancers to Treat

Recurrent glioblastoma is among the most difficult malignancies to manage due to its aggressive behavior, rapid disease progression, and resistance to conventional therapies. Even after maximal surgical resection, radiation, and chemotherapy, nearly all glioblastoma multiforme (GBM) patients experience recurrence within 6 to 9 months. The prognosis remains extremely poor, with median survival after recurrence often limited to just 12-15 months, as reported in a 2025 systematic review.

Several factors contribute to this therapeutic challenge:

• - Tumor heterogeneity: GBM is highly heterogeneous at the molecular level, making it difficult for one-size-fits-all therapies to succeed.
• - Blood-brain barrier (BBB): The BBB limits the delivery of systemic treatments to the tumor site, reducing the effectiveness of many anticancer drugs.
• - Immunosuppressive microenvironment: Recurrent glioblastomas suppress immune system activity, preventing effective T cell response.
• - Therapy resistance: Tumor cells rapidly adapt to and evade chemotherapy, radiation, and targeted agents.
• - Diffuse infiltration: Unlike other tumors, GBM cells infiltrate surrounding healthy brain tissue, making complete surgical removal nearly impossible.

Comparison Table: Standard Treatments vs. Challenges in Recurrent GBM

This poor response to standard therapy has led researchers to explore immune-based solutions that overcome tumor defenses and reactivate the immune system – such as dendritic cell therapy, which, as previously noted, shows promise in prolonging survival where other methods have failed.

How Dendritic Cell Therapy Works Against Glioblastoma Tumor Cells

Dendritic cell therapy is a form of active specific immunotherapy that educates the patient's own immune system to detect and destroy glioblastoma tumor cells. This approach relies on dendritic cells – specialized immune cells responsible for identifying antigens and presenting them to T cells, which then mount a targeted attack.
In glioblastoma patients, dendritic cell therapy typically uses autologous dendritic cells pulsed with tumor antigens derived from the patient’s blood plasma. The goal is to "train" the immune cells to recognize the unique molecular features of the patient's cancer.
One of the most important contributions to this field came from Ralph M. Steinman, who was awarded the Nobel Prize in Physiology or Medicine in 2011 for his discovery of dendritic cells and their role in adaptive immunity. His research laid the foundation for using dendritic cells as therapeutic vaccines in cancers like glioblastoma multiforme.

How Dendritic Cell Vaccines Are Created

Once injected, these tumor lysate loaded dendritic cells present glioblastoma-specific antigens to T cells, activating a strong and highly personalized immune response. This immune activation helps the body recognize, track, and attack glioblastoma tumor cells, potentially slowing disease progression and extending survival.

Survival Benefits: Clinical Evidence in Recurrent Glioblastoma Patients

Clinical data support the use of dendritic cell therapy as a means to achieve statistically significant extension of survival in patients with recurrent glioblastoma.
For example, a recent international phase III cohort trial evaluating autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) demonstrated substantial improvements in both median overall survival (OS) and long-term survival outcomes in glioblastoma patients treated across multiple centers.
In this trial, published in JAMA Oncology in 2023, median OS among patients with recurrent glioblastoma who received dendritic cell therapy was 13.2 months, compared to 7.8 months in the matched external control group. This group was derived from contemporaneous control groups in prior randomized clinical trials – representing a 68% increase in survival.
Moreover, long-term survival outcomes – reported as a secondary outcome in the trial – improved substantially, with 20.7% of treated patients alive at 24 months after recurrence, compared to 9.6% in the control group. A sensitivity analysis was conducted to confirm the findings across treatment centers and subpopulations, further validating the observed survival benefit.
In addition, a peer-reviewed analysis reinforced these findings by emphasizing the durable benefits seen in both newly diagnosed and recurrent cases. It noted that despite historical stagnation in glioblastoma outcomes, dendritic cell vaccines may be initiating the first significant improvements in decades. It is important to add that institutions, such as Tufts Medical Center, have emphasized the growing importance of personalized vaccine therapy in glioblastoma as part of evolving immunotherapeutic frameworks.

Summary of Key Outcomes in Recurrent Glioblastoma

These results highlight the growing recognition of dendritic cell therapy as a promising strategy for extending life expectancy in glioblastoma patients who previously had very limited options after recurrence. However, subgroup analysis showed that the benefit was particularly pronounced in individuals with favorable immune markers and minimal residual tumor burden.

Who Is Eligible for Dendritic Cell Immunotherapy?

Dendritic cell therapy is currently considered an advanced treatment option for both newly diagnosed glioblastoma patients and those with recurrent or progressive disease. Eligibility depends on multiple clinical and biological factors that determine whether a patient's immune system is capable of generating a meaningful response to the vaccine.
As discussed earlier, studies show that patients with recurrent glioblastoma tend to gain the most evident survival benefits. However, high grade glioma patients with newly diagnosed disease – especially when treated shortly after tumor resection – may also benefit from early immunological intervention when combined with standard care.

Common Inclusion Criteria

Because dendritic cell vaccines are highly personalized, early planning is critical. To ensure the presence of sufficient tumor antigens for vaccine development, blood must be drawn and processed under tightly controlled conditions shortly after diagnosis or during the initial treatment phase. This allows immune cells to be harvested and exposed to tumor-derived antigens contained in the patient's plasma.
This is why patients with newly diagnosed glioblastoma should undergo early immune profiling and eligibility screening if they are considering this therapy. Timely intervention increases the likelihood of vaccine success by maximizing immune responsiveness and minimizing tumor progression prior to the first dose.

Safety Profile: How Well Is Dendritic Cell Vaccination Tolerated?

Dendritic cell vaccination is generally well tolerated by glioblastoma patients, with most adverse events falling into Grade 1 or 2 on the Common Terminology Criteria for Adverse Events (CTCAE) scale – indicating mild to moderate severity. Unlike systemic chemotherapy, which often leads to hair loss, nausea, and bone marrow suppression, dendritic cell therapy stimulates the immune system in a targeted and personalized manner, resulting in fewer and less intense side effects.

Most common adverse events reported:

• - Fever or mild chills (transient and self-resolving);
• - Fatigue (typically short-term, resolving within 1-2 days);
• - Localized injection site reactions (redness, swelling, or tenderness);
• - Low-grade flu-like symptoms.

In rare cases, overstimulation of the immune system may occur, leading to temporary inflammatory responses such as mild lymph node enlargement or transient autoimmune-like symptoms. However, no serious adverse events or systemic infections – such as lymph node infection – have been consistently associated with dendritic cell vaccination in glioblastoma trials, as reported in a 2021 study published in Frontiers in Immunology.
Compared to the toxic profiles of chemotherapy or some immune checkpoint inhibitors, dendritic cell therapy offers a favorable safety profile, making it especially valuable for patients with already compromised health due to disease burden or prior treatments.
It is necessary to mention that the low incidence of complications contributes to greater treatment adherence and improved quality of life for glioblastoma patients.

What Is the Future of Glioblastoma Treatment?

As traditional therapies reach their limits, the future of glioblastoma treatment is shifting toward immune-based strategies. Dendritic cell vaccines have already demonstrated encouraging results, but researchers are now exploring how they can be enhanced through combination therapy with other forms of immunotherapy and molecularly targeted approaches.
One direction involves pairing dendritic cell vaccines with immune checkpoint inhibitors – agents that block inhibitory pathways such as PD-1/PD-L1, allowing T cells to sustain an enhanced immune response. Though checkpoint inhibitors have shown modest efficacy alone in glioblastoma, their potential when combined with vaccine therapy is under active investigation.

Emerging Immunotherapy Strategies

As mentioned above, the expanding number of randomized controlled trials (RCTs) and systematic reviews confirms growing scientific interest. Therefore, we can expect that many studies will prioritize combinatorial approaches – targeting multiple molecular mechanisms simultaneously to overcome the tumor's defense barriers.

How Booking Health Helps You Access Dendritic Cell Therapy Abroad

While dendritic cell therapy offers hope for patients with glioblastoma multiforme, access to this advanced treatment remains limited in many countries due to regulatory restrictions, lack of infrastructure, or high costs. Booking Health, a certified international medical coordination platform, helps patients treated for both diagnosed and recurrent glioblastoma receive world-class care at leading clinics in Germany and other European countries.
As a global leader in medical travel, Booking Health facilitates access to certified hospitals that specialize in dendritic cell therapy, ensuring each patient is matched with experienced neuro-oncologists and immunotherapy teams. Whether you are seeking treatment as a newly diagnosed patient or after recurrence, their personalized, end-to-end support organizes every aspect of your care journey.

What Booking Health offers:

• - Individual eligibility screening: Medical experts assess your diagnosis, immune status, and overall clinical profile to determine suitability for dendritic cell therapy.
• - Access to top neuro-oncology centers: Including German clinics known for offering dendritic cell-based immunotherapy and personalized cancer treatment.
• - Complete logistical support: From visa processing and interpreter services to airport transfers and accommodation, everything is arranged for your comfort.
• - Transparent pricing: Pre-negotiated rates and no hidden fees.
• - Long-term care coordination: Booking Health ensures follow-up communication between you and the treating clinic, supporting continuity of care after you return home.

If you or your loved one is facing a diagnosis of recurrent or newly diagnosed glioblastoma, you do not have to navigate this journey alone. Booking Health can help you access the latest advances in dendritic cell therapy at internationally certified clinics specializing in immunotherapy and neuro-oncology.
From eligibility criteria screening and treatment planning to travel and post-therapy follow-up, Booking Health handles every detail with compassionate care.

Learn more about how to access glioblastoma treatment abroad with Booking Health and take the first step toward advanced, personalized care.

Key Takeaways: Immunotherapy's Role in Recurrent Glioblastoma

For patients with recurrent glioblastoma, dendritic cell immunotherapy provides clinically meaningful benefits where standard therapies have failed. By utilizing the power of the immune system – specifically the precision of T cells activated by tumor lysate loaded dendritic cells – this therapy provides a highly personalized, less toxic alternative to standard care for patients with this aggressive brain cancer.

• - Dendritic cell therapy significantly extends survival, especially in patients with recurrent glioblastoma;
• - It activates the body's immune cells to recognize and attack tumor tissue;
• - Safer and better tolerated than traditional chemotherapy or radiation;
• - Proven effective for both recurrent and newly diagnosed glioblastoma patients;
• - Booking Health provides coordinated access to advanced immunotherapy at top European hospitals.

As immunotherapy continues to evolve, it brings hope to glioblastoma patients worldwide – especially when delivered through experienced clinical networks abroad.

About Booking Health

Booking Health™ is the international platform for rapid access to innovative treatments in the world’s leading certified clinics. Our network features over 250 top-tier hospitals across the globe, all distinguished by the exceptional levels of medical accreditation and expertise. By arranging care with the help of Booking Health company, you benefit from comprehensive medical support based on the latest innovations and personalized coordination. We offer cost saving up to 70% compared to direct booking via clinics — all without compromising on quality. Choosing Booking Health means more than just acquiring access to innovative world-class therapy - it means saving valuable time knowing that every detail is handled by professionals. Headquartered in Bad Hönningen, Germany and officially registered in Düsseldorf under HRB 106466, Booking Health proudly consults patients from over 75 countries for over a decade, offering services in 11 languages. 

Press inquiries

Booking Health
https://bookinghealth.com/
Lena Hanten
marketing@bookinghealth.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.